This is a double-masked, placebo-controlled study which will determine the action of NCX 470 ophthalmic solution, 0.1% on aqueous humor dynamic parameters in healthy volunteers or subjects with OHT.

开始日期2023-12-12

申办/合作机构

Nicox Ophthalmics, Inc.

CTR20223164

/ Completed临床1期

0.1%NCX 470 滴眼液在中国健康志愿者中的全身药代动力学、安全性和耐受性研究

主要目的：评价0.1% NCX 470滴眼液单次和多次给药在中国健康受试者中的药代动力学特征次要目的：评价0.1% NCX 470滴眼液单次和多次给药在中国健康受试者中的安全性和耐受性

开始日期2023-02-22

申办/合作机构

Nicox Ophthalmics, Inc.

[+2]

CTR20211277

/ Active, not recruiting临床3期

在开角型青光眼或高眼压症受试者中比较NCX 470与拉坦前列素0.005%的有效性和安全性的研究

本研究的主要目的是证明NCX 470滴眼液(0.1%)QD不劣于拉坦前列素滴眼液(0.005%)QD

开始日期2021-12-14

申办/合作机构

Nicox Ophthalmics, Inc.

[+2]

100 项与 Bimatoprost grenod 相关的临床结果

登录后查看更多信息

100 项与 Bimatoprost grenod 相关的转化医学

登录后查看更多信息

100 项与 Bimatoprost grenod 相关的专利（医药）

登录后查看更多信息

项与 Bimatoprost grenod 相关的文献（医药）

2024-12-01·Contemporary Clinical Trials

A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study

Article

作者: Mansberger, Steven L ; Hubatsch, Doug ; Fechtner, Robert ; Lopez, Krisi

PURPOSE:

To identify the optimal dose of NCX 470, a nitric oxide (NO)-donating bimatoprost, for comparison to latanoprost in a phase 3 trial for open-angle glaucoma (OAG) or ocular hypertension (OHTN) using an adaptive dose selection design.

PATIENTS AND METHODS:

In this prospective, multicenter trial, subjects were randomized 1:1:1 to NCX 470 0.065 %, NCX 470 0.1 %, or latanoprost 0.005 % dosed topically to both eyes once daily. After at least 30 subjects were assigned to each group, interim analysis was undertaken at 2 weeks and an independent committee selected the final NCX 470 dose for the full 12-week trial.

RESULTS:

The interim analysis included 103 subjects. The least-squares mean (95 % confidence interval [CI]) difference in diurnal intraocular pressure (IOP) was -1.51 mmHg (-2.88, -0.14) in the NCX 470 0.065 % group (p = 0.0308) and - 1.71 mmHg (-3.04, -0.38) in the NCX 470 0.1 % group (p = 0.0123), both favoring NCX 470 over latanoprost. The most common side effect was conjunctival/ocular hyperemia, the frequency and severity of which were similar in both NCX 470 dosing groups (p > 0.05). NCX 470 0.1 % was selected as the final dose and the NCX 470 0.065 % dose arm was terminated with subsequent subjects randomized 1:1 to NCX 470 0.1 % or latanoprost.

CONCLUSION:

Both concentrations of the NO-donating bimatoprost NCX 470 lower IOP more than latanoprost following 2 weeks of daily therapy. This adaptive dose selection design allowed identification of the optimal dose of NCX 470 with reduced trial costs, recruitment time, and the number of patients exposed to study medication.

2024-08-01·Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics

NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs

Article

作者: Unser, Andrea ; Ahmed, Feryan ; Hubatsch, Douglas A ; Impagnatiello, Francesco ; Torrejon, Karen Y ; Bastia, Elena ; Galli, Corinna ; Toris, Carol ; Fan, Shan

Purpose: To determine NCX 470 (0.1%) and Lumigan^® (bimatoprost ophthalmic solution, 0.01%-LUM) intraocular pressure (IOP)-lowering activity after single or repeated (5 days) dosing along with changes in aqueous humor (AH) dynamics. Methods: Ocular hypotensive activity of NCX 470 and LUM was compared with vehicle (VEH) in Beagle dogs using TonoVet^®. Non-human primates (NHP) and bioengineered three-dimensional (3D) human Trabecular Meshwork/Schlemm's Canal (HTM/HSC™) constructs exposed to transforming growth factor-β2 (TGFβ2) were used to monitor NCX 470 and LUM-induced changes in AH dynamics. Results: NCX 470 (30 μL/eye) showed greater IOP reduction compared with LUM (30 μL/eye) following single AM dosing [maximum change from baseline (CFB_max) = -1.39 ± 0.52, -6.33 ± 0.73, and -3.89 ± 0.66 mmHg (mean ± standard error of the mean) for VEH, NCX 470, and LUM, respectively]. Likewise, repeated 5 days daily dosing of NCX 470 resulted in lower IOP than LUM across the duration of the study (average IOP decrease across tests was -0.45 ± 0.22, -6.06 ± 0.15, and -3.60 ± 0.22 mmHg for VEH, NCX 470, and LUM, respectively). NCX 470 increased outflow facility (Cfl) in vivo in NHP (Cfl_VEH = 0.37 ± 0.09 μL/min/mmHg and Cfl_NCX470 = 0.64 ± 0.17 μL/min/mmHg) as well as in vitro (C_HTM/HSC) in HTM/HSC constructs (C_HTM/HSC__VEH = 0.47 ± 0.02 μL/min/mm²/mmHg and C_HTM/HSC__NCX470 = 0.76 ± 0.03 μL/min/mm²/mmHg). In addition, NCX 470 increased uveoscleral outflow (Fu_VEH = 0.62 ± 0.26 μL/min and Fu_NCX470 = 1.53 ± 0.39 μL/min with episcleral venous pressure of 15 mmHg) leaving unaltered aqueous flow (AHF_VEH = 2.03 ± 0.22 μL/min and AHF_NCX470 = 1.93 ± 0.31 μL/min) in NHP. Conclusions: NCX 470 elicits greater IOP reduction than LUM following single or repeated dosing. Data in NHP and 3D-HTM/HSC constructs suggest that changes in Cfl and Fu account for the robust IOP-lowering effect of NCX 470.

2024-08-01·AMERICAN JOURNAL OF OPHTHALMOLOGY

A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study

Article

作者: Mansberger, Steven ; Ziebell, Sara ; Lopez, Krisi ; Hubatsch, Doug ; Fechtner, Robert ; Mulaney, Jay ; Branch, James

PURPOSE:

To compare intraocular pressure (IOP)-lowering efficacy and safety of NCX 470, a nitric oxide (NO)-donating bimatoprost, to latanoprost in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

DESIGN:

Prospective, phase 3, randomized, adaptive dose-selection, double-masked, parallel-group trial.

METHODS:

691 subjects with OAG or OHT and unmedicated IOP ≥26 mmHg at 8AM, ≥24 mmHg at 10AM, and ≥22 mmHg at 4PM in the study eye were randomized to NCX 470 0.065%, NCX 470 0.1%, or latanoprost 0.005%. An interim analysis was performed to select the final dose of NCX 470. We evaluated noninferiority of NCX 470 versus latanoprost, based on IOP reduction from baseline at 8AM and 4PM at 2 weeks, 6 weeks, and 3 months.

RESULTS:

661 subjects were analyzed; IOP was significantly reduced at all on-treatment time points, with reductions ranging from 8.0 to 9.7 mmHg (P < .0001 at each time point) in the NCX 470 0.1% group. Mean IOP reductions were greater with NCX 470 0.1% than latanoprost 0.005% at all 6 time points and significantly greater (P < .05) at 4 of the 6 time points. The most common adverse event was conjunctival/ocular hyperemia.

CONCLUSION:

The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.

项与 Bimatoprost grenod 相关的新闻（医药）

2025-03-19

·GlobeNewswire-Health Care

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025 March 19, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient completed their final visit in the Whistler Phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in intraocular pressure (IOP) lowering. The Whistler Phase 3b trial enrolled 18 healthy volunteers with ocular hypertension in a double-masked, placebo-controlled study investigating the action of NCX 470 on aqueous humor parameters including trabecular meshwork outflow and episcleral venous pressure. Each subject participated in the trial for approximately 8 days.About NCX 470NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the two Phase 3 clinical trials, have been extensively published and are available on our website. The second Phase 3 clinical trial, Denali, is currently ongoing. The last American patient in Denali has completed their final visit, with Chinese patients completing theirs, and the results are expected in Q3 2025. Mont Blanc and Denali have been designed to fulfill the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China, where NCX 470 is exclusively licensed to Ocumension Therapeutics. NCX 470 is also licensed exclusively to Kowa for Japan. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_WhistlerLPLV_19March2025_PR_FINAL

临床3期

2025-01-28

·GlobeNewswire-Health Care

Nicox Announces Scientific Presentation and Conference Attendance in H1 2025

Press Release Nicox Announces Scientific Presentation and Conference Attendance in H1 2025January 28, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced a presentation at the upcoming American Glaucoma Society (AGS) Annual Meeting 2025 and participation in a number of key ophthalmology and financial conferences in the first half of 2025. Presentation of additional analysis of the NCX 470 Mont Blanc Phase 3 Clinical trial AGS 2025 Annual Meeting – February 26 to March 2, 2025, Washington, U.S. Poster Title: Diurnal Intraocular Pressure Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC TrialType: Poster Presentation Session Date: Saturday March 1, 2025 from 7:00 am to 8:00 am (local time). Presenter: Dr. Robert Fechtner, Chair of the Department of Ophthalmology at SUNY Upstate Medical University in Syracuse, NY Upcoming Conference Attendance Allinvest securities Biomed Forum – February 4, 2025 – Paris, France Investor Access – April 1-2, 2025 – Paris, France Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting – May 4-8, 2025 – Salt Lake City, Utah, U.S.BIO International Convention – June 16-19, 2025 – Boston, MA, U.S. Members of the management team will be available for one-on-one meetings at these events. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.com Analyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_H1_2025_CONFERENCES_PR_FINAL

临床3期

2025-01-21

·GlobeNewswire-Health Care

Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights

Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial with topline results expected in Q3 2025 Fourth quarter 2024 Nicox Group revenue of €13.7 million Cash of €10.7 million as of December 31, 2024, following a €5.2 million debt repayment, which the Company estimates will finance it into the third quarter of 2025 January 21, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided financial and business highlights for the fourth quarter of 2024 for Nicox SA and its subsidiaries (the “Nicox Group”). The Company does not report consolidated financial statements but discloses Nicox Group figures for information purposes only.“The final patient was enrolled into the Denali clinical trial in the last days of 2024 and we are therefore starting the year fully financed to complete this pivotal trial, with the results expected to be announced in the third quarter. Having maintained our timelines and stabilised our financial situation in the last 12 months, we are now focussing on the future direction of the company and the partnerships for the commercialization of NCX 470 in key territories outside of our collaborations with Ocumension and Kowa, principally the United States.” said Gavin Spencer, Chief Executive Officer of Nicox. Revenue, Cash Position for the Nicox Group for the Fourth Quarter 2024 and post-period events The last patient in the NCX 470 Denali Phase 3 trial has been recruited and topline results remain expected in Q3 2025.Nicox Group revenue for the fourth quarter of 2024 was €13.7 million, almost entirely consisting of proceeds from the sale of the VYZULTA royalty. Due to the sale of the VYZULTA royalty the Nicox Group received no material royalty revenue in the fourth quarter of 2024, compared1 to €2.2 million for the fourth quarter 2023, consisting entirely of royalty revenue. The accounting treatment of the proceeds from the sale of the VYZULTA royalty has not yet been determined. The Nicox Group had cash of €10.7 million at 31 December compared to €19.7 million at 30 September 2024 (including the estimated net proceeds from the VYZULTA royalty sale and accompanying investment in October 2024). The significant cash consumption is due to the partial repayment of the Company’s principal debt, set out below. Based on this cash position and expected milestone income from existing agreements the Company estimates that it is financed into the third quarter of 2025, including the topline results from the Denali trial. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company and the ability to complete the Denali clinical trial.As of December 31, 2024, the Nicox Group had financial debt of €15.1 million (entirely held by Nicox SA), consisting of €14.2 million in the form of a bond financing agreement with Kreos Capital (an affiliate of BlackRock), and a €0.9 million credit agreement guaranteed by the French State, and granted in the context of the COVID-19 pandemic. Nicox repaid €5.2 million of the Kreos Capital debt following the sale of the VYZULTA royalty in October 2024. The Company continues to evaluate all options for non-dilutive and dilutive financing to extend its cash runway. In particular, the Company is actively exploring multiple strategic options which could facilitate the development and commercialization of its product candidate NCX 470 and the future growth of the Company. Key Future Milestones Whistler Phase 3b clinical trial, initiated in December 2023, investigating NCX 470’s dual mechanism of action (nitric oxide and prostaglandin analog) in intraocular pressure lowering: results are currently expected in the first quarter of 2025.  Denali Phase 3 clinical trial evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension: The last patient has been recruited and topline results are expected in Q3 2025.  All figures in this press release are non-audited. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 1 Revenue has previously been reported as net of royalty payments made by Nicox, which applied only to VYZULTA revenue. Following the sale of the VYZULTA revenue, Nicox will report only the gross revenue figures. Attachment EN_FY2024Q42024_PR_January 21 2025_FINAL

财报临床3期

100 项与 Bimatoprost grenod 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高眼压症	临床3期	中国	苏州欧康维视生物科技有限公司	2022-01-30
开角型青光眼	临床3期	美国	Nicox Ophthalmics, Inc.	2020-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04445519 (MONT BLANC, Literature) 人工标引	临床3期	开角型青光眼 \| 高眼压症	103	NCX 470 0.065 %	醖築網蓋鹹蓋壓淵鹹齋(蓋襯夢繭蓋壓鹹構遞築) = The most common side effect was conjunctival/ocular hyperemia, the frequency and severity of which were similar in both NCX 470 dosing groups (p > 0.05). 鑰鬱夢製齋窪網構構糧 (選獵選網鬱繭餘鬱餘構 )	积极	2024-12-01
				NCX 470 0.1 %
ARVO2023	N/A	氧自由基损伤	-	NCX 470 (0.1% bid)	簾鑰蓋鹽獵衊淵衊構壓(選獵願齋鏇鏇廠積餘膚) = 遞廠網鹽選鏇範憲鹹齋襯製築鑰憲鏇網顧遞壓 (鏇蓋顧築獵築觸糧願鹹 )	-	2023-04-23
				Lumigan® (bimatoprost 0.01%, ophthalmic solution)	簾鑰蓋鹽獵衊淵衊構壓(選獵願齋鏇鏇廠積餘膚) = 鑰膚鏇製蓋築製鑰築壓襯製築鑰憲鏇網顧遞壓 (鏇蓋顧築獵築觸糧願鹹 )
NCT03657797 (Dolomites, CTgov)	临床2期	开角型青光眼	656	NCX 470 (NCX 470 0.021%)	壓選選餘製顧夢鹹淵鏇(艱鬱鑰淵構壓鬱鹹鹹製) = 範願衊鹹壓衊顧遞醖艱製獵壓窪鹽廠鏇繭蓋築 (構製衊夢齋構齋鬱蓋鏇, 2.606) 更多	-	2022-12-08
				NCX 470 (NCX 470 0.042%)	壓選選餘製顧夢鹹淵鏇(艱鬱鑰淵構壓鬱鹹鹹製) = 築構積鏇鏇窪艱製醖簾製獵壓窪鹽廠鏇繭蓋築 (構製衊夢齋構齋鬱蓋鏇, 2.511) 更多
NCT04445519 (Mont Blanc, Corporate Publications) 人工标引	临床3期	青光眼	691	NCX 470	顧窪願襯範網壓廠膚顧(鹹構窪選醖網鬱壓製鏇) = 範鬱艱夢築衊鹽醖鏇觸窪餘齋鏇願觸廠獵遞壓 (窪鹽憲築膚積構襯鹹鑰 ) 更多	非劣	2022-10-31
				Latanoprost	顧窪願襯範網壓廠膚顧(鹹構窪選醖網鬱壓製鏇) = 鏇觸糧觸簾選憲構構鹹窪餘齋鏇願觸廠獵遞壓 (窪鹽憲築膚積構襯鹹鑰 ) 更多
ARVO2022	N/A	-	-	NCX 470 0.1%	鏇夢構鬱製願鹽網窪窪(淵構鬱網鹹窪膚構願願) = 鬱積醖鑰壓網糧衊鹹齋觸襯鹹夢遞願蓋範選獵 (壓製觸築膚製壓遞鹹鹽 ) 更多	-	2022-05-01
				Vehicle	鏇夢構鬱製願鹽網窪窪(淵構鬱網鹹窪膚構願願) = 構艱淵獵網鏇襯顧積鹽觸襯鹹夢遞願蓋範選獵 (壓製觸築膚製壓遞鹹鹽 ) 更多
NCT03657797 (Dolomites, AAO2020)	临床2期	低眼压	433	NCX 470 0.021%	繭簾製獵鹹簾願齋憲壓(簾廠壓淵餘範觸鑰鹹鑰) = The most common adverse event was conjunctival hyperemia. There were no treatment-related serious adverse events or treatment-related systemic adverse events 糧壓襯糧鏇廠選廠簾壓 (窪糧淵糧糧糧觸壓築糧 )	积极	2020-11-13
				NCX 470 0.065%
NCT03657797 (Dolomites, GlobeNewswire) 人工标引	临床2期	青光眼	433	NCX-470	艱遞蓋鏇鹽簾膚壓網鏇(壓築窪壓膚襯鏇衊齋鹽) = 獵積壓醖鹽糧鏇繭糧簾艱遞衊襯艱製選構齋鬱 (壓艱獵淵鹽廠願顧艱餘 ) 更多	积极	2019-10-02
				Latanoprost	艱遞蓋鏇鹽簾膚壓網鏇(壓築窪壓膚襯鏇衊齋鹽) = 築衊襯顧顧選廠鹹齋遞艱遞衊襯艱製選構齋鬱 (壓艱獵淵鹽廠願顧艱餘 ) 更多